Searchable abstracts of presentations at key conferences in endocrinology

ea0063oc2.4 | Diabetes 1 | ECE2019

Empagliflozin attenuates the progression of atherosclerosis in APO-E knockout mice

Dimitriadis Georgios K , Nasiri-Ansari Narjes , Agrogannis Georgios , Nikiteas Nikolaos , Kostakis Ioannis D , Kaltsas Gregory , Papavassiliou Athanasios G , Kassi Eva , Randeva Harpal S

Background: Sodium glucose co-transporter 2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with empagliflozin on biochemical and immunohistochemical markers related to atherosclerosis development in apolipoprotein E knockout [Apo-E(−/−)] mice.Methods: At the ag...

ea0059p085 | Diabetes & cardiovascular | SFEBES2018

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice

Dimitriadis Georgios K , Nasiri-Ansari Narjes , Agorogiannis Georgios , Perrea Despoina , Kostakis Ioannis D , Papavassiliou Athanasios G , Kaltsas Gregory , Kassi Eva , Randeva Harpal S

Sodium glucose co-transporter2 (SGLT2) inhibitors reduce the incidence of cardiovascular events in patients with Type 2 Diabetes Mellitus (T2DM) based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with canagliflozin on biochemical and immunohistochemical markers related to atherosclerosis and atherosclerosis development in the aorta of Apolipoprotein E knockout (Apo-E(−/−)) mice. After...

ea0073aep63 | Adrenal and Cardiovascular Endocrinology | ECE2021

Prognostic factors in Adrenocortical Carcinoma: A single institution case-series

Parianos Christos , Kyriakopoulos Georgios , Kostakis Ioannis D. , Nasiri-Ansari Narjes , Aggeli Chrysanthi , Angelousi Anna , Choreftaki Theodosia , Papavassiliou Athanasios G. , Kaltsas Gregory , Zografos Giorgos , Kassi Evanthia

BackgroundAdrenocortical carcinoma (ACC) is a rare but very aggressive endocrine malignancy with poor survival. Histopathology is important for diagnosis, while in some cases immunohistochemical markers and gene profiling of the resected tumor may be superior to current staging systems to determine prognosis.AimHerein, we aimed to present the 20year experience at a tertiary Hospital in patients with ACCs and ...